Cipla and Glenmark Recall Drugs from US Market: Packaging Flaw and Quality Concerns

Manufacturing Issues Prompt Recall of Drugs by Companies Cipla and Glenmark

Due to manufacturing issues, companies in the United States are recalling their drugs from the American market. The New Jersey-based company Cipla has recalled 59,244 packs of Epratropium Bromide and Albuterol Sulfate Inhalation Solution. This action follows a notification from the US Food and Drug Administration (USFDA).

Cipla’s drugs are being recalled due to “short fill” issues. According to the USFDA, the quantity of medication in these drug pouches was found to be below the specified limit. Additionally, there were leaks in the pouches.

Production of These Drugs Was Conducted in India

These drugs were manufactured in a Special Economic Zone (SEZ) plant in the city of Indore, India. They are used to manage symptoms of respiratory diseases such as asthma, chronic bronchitis, and emphysema.

Glenmark Recalls High Blood Pressure Medication

Glenmark Pharmaceuticals Inc., the U.S. subsidiary of Glenmark, has recalled 3,264 bottles of diltiazem hydrochloride capsules used to control high blood pressure. The medication was being manufactured to alleviate symptoms of hypertension.

The company initiated the recall starting April 17, 2024, due to certain shortcomings in the manufacturing process. According to announcements by the US Food and Drug Administration (USFDA), the recall is not expected to cause any significant harm from the affected medications.

Cipla Industries Ltd.

Cipla is the second-largest pharmaceutical manufacturing company in India. It operates 47 manufacturing units across the globe and supplies its products to 86 countries worldwide. With a market capitalization of ₹1.15 lakh crore,Cipla is a major player in the pharmaceutical industry.

Leading Supplier of Generic Medicines in India

India is the largest supplier of generic medicines, producing drugs under 60,000 different generic brands across 60 medical categories. The country accounts for 20% of the total global pharmaceutical production. Indian-manufactured drugs are supplied to over 200 countries worldwide, including Japan, Australia, Western Europe, and the United States.